David J. Clark, M.D. has served as our Chief Medical Officer since January 2016. He has over 20 years of global industry experience in biopharmaceutical companies based in the United States and Europe. Prior to joining Aldeyra, Dr. Clark served as the Chief Medical Officer of Wilson Therapeutics, a privately-held biotechnology company developing novel pharmaceuticals to treat Wilson Disease, a rare autosomal recessive disorder of copper metabolism. He served in similar roles from 2009, initially as Chief Medical Officer at NormOxys Inc., and then at TransTech Pharma, LLC. Previously, Dr. Clark held clinical leadership roles of increasing responsibility at Pfizer Inc. from 2001 to 2009 and at GlaxoSmithKline plc from 1997 to 2001. Dr. Clark received his medical degree from the University of Edinburgh, trained in internal medicine and conducted respiratory medicine academic research in the UK before moving into pharmaceutical industry research.